Organization (Industry)
MERIT MEDICAL SYSTEMS, INC.
ClinicalTrials.gov lists MERIT MEDICAL SYSTEMS, INC. as lead sponsor of 31 trials, counting the companies grouped under it. MERIT MEDICAL SYSTEMS, INC. itself has 4 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers MERIT MEDICAL SYSTEMS, INC. and 3 companies grouped under it: 31 lead-sponsored trials (29 its own, 2 in the grouped companies) and 6 legal-entity registrations (2 its own, 4 in the grouped companies).
Companies grouped under this page (3)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Cianna Medical | 1 | 1 |
| KA Medical (United States) | 1 | 1 |
| Merit Medical (France) | 0 | 2 |
Disease areas (37)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Arteriovenous Fistula | 3 |
| Arteriovenous Malformations | 3 |
| Hemorrhage | 3 |
| Kidney Failure, Chronic | 3 |
| Renal Insufficiency, Chronic | 3 |
Showing 5 of 37 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 2 |
| 2016 | 1 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (4)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Corticosteroid (celestone) injection | Osteoarthritis | Not reported | 1 |
| Corticosteroid (celestone) injection | Osteoarthritis, Knee | Not reported | 1 |
| PTA (Standard of Care) | Arteriovenous Fistula | Not reported | 1 |
| PTA (Standard of Care) | Arteriovenous Malformations | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=12) | 13% on time (n=8) |
Journals published in (18)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Cardiovascular and interventional radiology | 3 |
| Journal of vascular surgery | 2 |
| Kidney international | 2 |
| Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | 2 |
| The journal of vascular access | 2 |
Showing 5 of 18 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 430 | 100 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 1,515,906,000 | 128,489,000 | 97,352,000 |
| 2024 | 1,356,514,000 | 120,357,000 | 87,466,000 |
| 2023 | 1,257,366,000 | 94,411,000 | 82,728,000 |
| 2022 | 1,150,981,000 | 74,516,000 | 75,510,000 |
| 2021 | 1,074,751,000 | 48,454,000 | 71,247,000 |
| 2020 | 963,875,000 | -9,843,000 | 57,537,000 |
| 2019 | 994,852,000 | 5,451,000 | 65,615,000 |
| 2018 | 882,753,000 | 42,017,000 | 59,532,000 |
| 2017 | 727,852,000 | 27,523,000 | 51,403,000 |
| 2016 | 603,838,000 | 20,121,000 | 45,229,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (17)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-01 | Other financing | not disclosed | Sec extracted |
| 2026-01-07 | Other financing | not disclosed | Sec extracted |
| 2025-10-15 | Other financing | not disclosed | Sec extracted |
| 2025-05-20 | Other financing | not disclosed | Sec extracted |
| 2024-11-01 | Other financing | not disclosed | Sec extracted |
Showing 5 of 17 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 22 |
FDA recalls (145)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Splashwire Hydrophilic Guide Wire: REF: MSWSTDA35150 UDI-DI codes: 00884450529645 00884450529669 00884450529690 REF: MSWSTDA35180 UDI-DI codes: 00884450529645 00884450529669 REF: MSWSTDA35260EX UDI-DI code: 00884450529683 REF: MSWSTDA3580 UDI-DI codes: 00884450529645 00884450529690 00884450529744 REF: MSWSTDS35150 UDI-DI codes: 00884450529690 00884450529744 REF: MSWSTFA35260EX UDI-DI code: 00884450529447 REF: MSWSTFA3580 UDI-DI code: 00884450529515 REF: MSWSTFS35150 UDI-DI code: 00884450529553 The Merit Hydrophilic Guide Wire is intended to be used in the peripheral vascular system to facilitate the placement of devices during diagnostic and interventional procedures. | Class II | 2026-05-08 |
| Philips Bridge Prep Kit REF: K12-09098B Sterile EO, Rx ONLY | Class II | 2026-04-02 |
| Philips Bridge Prep Kit REF: K12-09098C Sterile EO, Rx ONLY | Class II | 2026-04-02 |
| Philips Bridge Prep Kit REF: K12-09098C Sterile EO, Rx ONLY | Class II | 2026-04-02 |
| CentrosFLO Hemodialysis Catheters, REF: CENFP15K/A, CENFP15K/B, CENFP17K/A, CENFP19K/A, CENFP23K/A, CENFP27K/A, CENFP31K/A, CENFT15K, CENFT15K/D, CENFT17K, CENFT17K/A, CENFT17K/D, CENFT19K, CENFT19K/A, CENFT19K/B, CENFT19K/D, CENFT23K, CENFT23K/A, CENFT23K/B, CENFT23K/D, CENFT27K, CENFT27K/A, CENFT27K/B, CENFT27K/D, CENFT31K, CENFT31K/A, CENFT31K/B, CENFT31K/D | Class I | 2026-02-13 |
Showing 5 of 145 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 3 | 2022-05-23 |
Manufacturing and distribution sites (4)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| MERIT MEDICAL SYSTEMS, INC | Chester, US | FDA | |
| Merit Medical Systems, Inc. | Houston, US | FDA | |
| Merit Medical Systems, Inc. | ALISO VIEJO, US | FDA | |
| MERIT MEDICAL SYSTEMS, INC. | South Jordan, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (7)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Johns Hopkins University | Co sponsors trial with | 1 |
| PENTAX Medical Company (United States) | Co sponsors trial with | 1 |
| Lahey Hospital and Medical Center | Co sponsors trial with | 1 |
| University of North Carolina System | Co sponsors trial with | 1 |
| Varian Medical Systems (United States) | Co sponsors trial with | 1 |
Showing 5 of 7 relationships.
Latest dated events (654)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-08 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-02 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-02 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-02 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-01 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 654 events.
Biomarker capability evidence (27)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| APC | Trial collaborator | Named in trial inclusion criteria |
| GUCY2C | Trial sponsor | Named in trial inclusion criteria |
| HGD | Trial collaborator | Named in trial inclusion criteria |
| HGD | Trial sponsor | Named in trial inclusion criteria |
| KLK3 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 27 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, approved assets, fda warning letters, fda untitled letters, clia clinical laboratory certificates, and biomarkers this organization publishes on.